In a report prepared by NCB Stockbrokers, senior analyst Dr Orla Hartford has reviewed the data available in Elan drug Tysabri's Biological License Application (BLA) in an attempt to understand why PML developed in two multiple sclerosis patients on Tysabri and AVONEX combination treatment.